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AbstrAct
Background: The aim of this research was to study the overall restoration 
effect on residual retinal cells through surgically grafted autologous cells onto the 
surrounding tissue, choroid and retina in order to produce a constant secretion of 
growth factors (GFs) in dry age-related macular degeneration (AMD) patients.  
Results: 6 months after surgery, several values were statistically significant 
in the group with higher RTA. Also patient compliance analysis (PCA) in relation to 
functional change perception appeared to be very good.
Methods: Thirty-six eyes of 25 patients (range 64-84 years of age) affected 
by dry AMD were included in study, and divided in two groups by spectral domain-
optical coherence tomography (SD-OCT): group A with retinal thickness average 
(RTA) less than 250 microns (µm) and group B with RTA equal to or more than 
250 µm. Adipocytes, adipose-derived stem cells from the stromal-vascular fraction, 
and platelets from platelet-rich plasma were implanted in the suprachoroidal space. 
Particularly, the following parameters were evaluated: best corrected visual acuity 
(BCVA) for far and near distance, retinal thickness maps, scotopic and photopic 
electroretinogram (ERG), and microperimetry (MY). All statistical analyses were 
performed with STATA 14.0 (Collage Station, Texas, USA).
Conclusions: The available set of GFs allowed biological retinal neuroenhancement. 
After 6 months it improved visual performance (VP), but the increase was better if 
RTA recorded by OCT was higher, probably in relation to the presence of areas with 
greater cellularity.
INtrODUctION
Age-related macular degeneration (AMD) is 
a heterogeneous clinical condition in which retinal 
degeneration occurs predominantly in the macula and 
leads to impairment of central visual acuity [1, 2]. AMD, 
the leading cause of blindness in people aged 55 years or 
older in developed countries, occurs in two general forms: 
1) Wet AMD involving choroidal neovascularization with 
subsequent bleeding and fluid exudation; 2) Dry AMD, 
which involves a constellation of clinical features that 
can include: drusen, pigment clumping, abnormalities 
of the retinal pigment epithelium (RPE), and geographic 
atrophy (GA) [1-3]. The latter can begin as a thinning of 
the RPE and lead subsequently to an atrophic change in 
the macula with loss of overlying photoreceptors [2-4]. As 
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a result, there is a reduction of best corrected visual acuity 
(BCVA), retinal sensitivity, retinal bioelectric activity, 
and then damage to visual performance (VP). Nowadays, 
spectral domain-optical coherence tomography (SD-OCT) 
has been added to electroretinographic exams on retina for 
more accurate morphological and functional studies [5].
Moreover, dry AMD accounts for 80% of all 
intermediate and advanced forms of the retinal disease 
and no effective treatment for progressive vision loss 
is available to date. On the other hand, the retina is 
particularly susceptible to oxidative damage due to its 
high oxygen demand and constant exposure to light. It 
is known that smoking may slow down choroidal blood 
flow, promoting ischemia, hypoxia, and microinfarctions, 
resulting in a reduction in macular pigments and in 
RPE damage. Oral supplement of antioxidants and 
smoking cessation can help to prevent or counter AMD 
development and progression [1-3]. However, dry AMD 
progression reduces VP causing discomfort to patients 
who become increasingly more visually impaired [3-4]. 
Consequently, the idea of using systemic or local 
injection of stem/progenitor or reparatory cells in the area 
of injury to treat multiple chronic disorders has received 
close attention in the last decade [6]. Unfortunately, 
the appropriate surgical procedure to graft cells in 
the subretinal space appears to be very complex and 
expensive, as well as potentially dangerous for the eye, 
as it undergoes invasive surgery. Instead, embryonic stem 
cells are not always ethically acceptable and not entirely 
free from the risks related to the use of immunosuppressive 
therapy [7].
Nevertheless, there is another aspect linked to 
the properties of growth factors (GFs) which have been 
known for many years and specifically to their ability to 
curb the evolution of retinal dystrophies in experimental 
models, as demonstrated by several studies. GFs and 
neurotrophins such as basic fibroblast growth factor 
(bFGF), neural growth factor (NGF), ciliar neurotrophic 
factor (CNTF) and brain-derived neurotrophic factor 
(BDNF), can significantly slow down retinal degeneration 
and cell death in animal models [7-10]. 
Based on these concepts, the efficacy of autologous 
fat transplantation was demonstrated by Filatov [11] work 
and Pelaez [12] first, and by Meduri et al. [13] and Limoli 
et al. later [14]. 
Our cellular autograft, defined Limoli Retinal 
Restoration Technique (LRRT), uses three different cell 
types that are able to produce adequate GFs in terms of 
both quantity and quality: 
Adipose stromal cells derived from orbital fat [15].
Platelets (PLT) derived from platelet-rich plasma 
(PRP) [16, 17].
Adipose-derived stem cells (ADSCs) included in the 
stromal-vascular fraction (SVF) of adipose tissue [18].
Cellular autograft efficacy in dry AMD was 
demonstrated by Limoli et al. in preliminary works [4, 19-
21]. Indeed, to curb the worsening of retinal dry AMD, we 
considered employing two important elements:
neurotrophic GFs to slow down RPE cells and 
photoreceptor apoptosis;
angiotrophic GFs for therapeutic purposes to 
improve choroidal flow; in fact, the impairment of the 
latter is belived to be one of the pathogenetic factors of 
AMD.
Consequently, the rationale of our study was focused 
on cell therapy, through autologous cells surgically grafted 
in the suprachoroidal space, in order to achieve a costant 
production of GFs at the chorioretinal level. Besides, to 
evaluate the prognosis of dry AMD patients treated with 
LRRT, we assumed that a greater number of residual cells 
leads to greater interaction between GFs and chorioretinal 
cellular membrane receptors, more intense cellular activity 
and, ultimately, improvement of VP. In other words, we 
hypothesized that if retina is thinner and more atrophic, it 
is harder to obtain functional neuroenhancement through 
cell therapy. In order to focus on this latter aspect of our 
research, we chose SD-OCT for the preliminary analysis 
of retinal thickness average (RTA) in cell therapy with 
LRRT on patients affected by dry AMD. 
rEsULts
In the study we included 36 eyes (21 right and 15 
left eyes) of 25 patients with dry AMD (9 men and 16 
women), aged between 64 and 84 years of age (75.96 
years on average) (SD ±6.13) (Table 1). Prior to cell 
autograft with LRRT, values of RTA and all components 
of ERG were recorded at time 0 (T0).
Based on RTA, all the eyes were divided into two 
groups according to normative data for macular thickness 
by high-definition SD-OCT (Table 1): [5]
• Group A, where RTA was less than 250 microns 
(µm), with 14 eyes, 10 patients (2 men and 8 
women), mean age of 77.6 years (range 64-84 
years of age, SD ±6.6) (Figure 1, left panel).
• Group B, where RTA was equal to or greater 
than 250 µm, with 22 eyes, 15 patients (7 men 
and 8 women), mean age of 74.87 years (range 
64-84 years of age, SD ±5.8) (Figure 1, right 
panel). 
No significant differences were found between the 
two groups either in terms of age (p = 0.284) or gender (p 
= 0.174) distribution. 
correlation with retinal thickness average (rtA) 
and electroretinogram (ErG)
ERG-recorded electrical activity (T0) in group A 
(Rod ERG = 38.1, Rod-cone ERG = 95.97, Cone ERG 
= 40.66) was lower than in group B (Rod ERG = 63.54, 
Rod-cone ERG = 131.54, Cone ERG = 47.37) (Figure 2). 
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RTA was positive correlated with Rod-cone ERG in group 
A (r = 0.59, p = 0.025), but not in group B (r = -0.29, p 
= 0.196). RTA was positive correlated with Rod ERG in 
group A (r = 0.69, p = 0.006) and group B (r = 0.53, p = 
0.011). (Figure 2).
Visual functional characteristics and patient 
compliance analysis (PcA)
The visual functional characteristics in patients with 
dry AMD and the average values recorded before (T0) 
and 6 months (T180) after cell autograft by LRRT are 
shown in Table 2. BCVA was measured by early treatment 
diabetic retinopathy study (ETDRS) charts at 4 meters in 
logarithm of the minimum angle of resolution (logMAR) 
units and visual acuity for near vision (close-up) in points 
(Pts) indicating the necessary zoom factor (X).
BCVA increased in group A from 0.621 logMAR 
to 0.588 logMAR and in group B from 0.59 logMAR to 
0.41 logMAR. Mean variation was significantly lower in 
A (0.033 logMAR SD 0.17) than in B (0.18 logMAR SD 
0.23) (Figure 1, 3A, 4) (Table 2). 
Close-up visus evaluated with magnifying system 
increased in both groups from T0 to T180. In group A, it 
went from 12.14 to 8.86 Pts with the same magnification 
(X 5.1) and a mean increase of 3.29 Pts (SD 7.35). 
In group B, visual acuity went from 8.68 to 8.27 Pts 
with slightly lower magnification (from 3.1 to 2.9 X), 
equivalent to an increase of 0.41 Pts (SD 2.0) (Figure 1, 
3B, and 4) (Table 2).
Average retinal sensitivity with microperimetry 
(MY) increased in both groups. The mean improvement in 
retinal sensitivity was 0.76 dB (SD 2.5), increasing from 
7.65 dB to 8.41 dB in group A, and 1.59 dB (SD 3.34), 
increasing from 16.82 dB to 18.4 in group B (Figure 1, 
3C, and 4) (Table 2). 
Patient compliance analysis (PCA) showed that, at 6 
months post surgery, 19 out of 36 eyes (52.78%) recorded 
better vision, 14 out of 36 (38.89%) no change in the 
functional situation, and 3 out of 36 (8.33%) a worsening 
(Table 3). Among the 19 eyes of the patients who noted 
an improvement at 6 months post surgery, 5 (26.3%) 
belonged to group A and 14 (73.7%) to group B. 
No adverse effects were reported in any case and 
mean values of the intraocular pressure recorded before 
and after surgery did not change significantly. 
table 1: baseline demographic and clinical characteristics by retinal thickness average (rtA) in patient group A 
(RTA<250 microns) and group B (RTA ≥250 microns).
Patient data Group A Group b total
Number of patients (N) N = 10 N = 15 N = 25
Female (%) 8 (80.0) 8 (53.3) 16 (64.0)
Male (%) 2 (20.0) 7 (46.7) 9 (36.0)
Number of eyes (right/left) 14 (8/6) 22 (13/9) 36 (21/15)
Average age (±SD) 77.6 (6.6) 74.87 (5.8) 76.0 (6.13) 
table 2: Mean values recorded before (t0) and 6 months (t180) after surgery with Limoli retinal restoration 
Technique (LRRT) for retinal thickness average (RTA) of group A (RTA<250 microns) and group B (RTA ≥250 
microns) and statistical significance.
Parameter Group A P value* Group b P value*
t0 t180 t0 t180
Mean (sD) Mean (sD)
BCVA (logMAR) 0.62 (0.57) 0.58 (0.56) 0.465 0.59 (0.39) 0.41 (0.3) 0.001
Close-up visus (Pts) 12.14 (12.3) 8.86 (5.36) 0.083 8.68 (2.87) 8.27 (3.33) 0.33
Close-up visus X 5.13 (4.44) 5.13 (4.08) 1.000 3.11 (3.39) 2.92 (3.48) 0.03
Retinal sensitivity 7.65 (4.83) 8.41 (4.75) 0.237 16.82 (3.2) 18.4 (3.4) 0.01
Parameter Group A Group b P value*
Mean changes (sD) % Mean changes (sD) %
BCVA (logMAR) 0.033 (0.17) 5.16% 0.18 (0.23) 30.51% 0.04
Close-up visus (Pts) 3.29 (7.35) 27.10% 0.41 (2.02) 4.72% 0.09
Close-up visus X 0 (1.95) 0% 0.19 (0.49) 6.10% 0.43
Retinal sensitivity 0.76 (2.51) 9.93% 1.59 (3.34) 9.45% 0.50
* Calculated by Mixed regression model taking into account multiple eyes for the same subjects. BCVA= best corrected 
visual acuity for far distance measured by early treatment diabetic retinopathy study (ETDRS) charts at 4 meters in logarithm 
of the minimum angle of resolution (logMAR) units; close-up visus = visual acuity for near vision in points (Pts) measured 
by magnifying system and necessary magnification, X = necessary magnification; Retinal sensitivity = measured by 
microperimetry (MY) in decibel (dB); SD = standard deviation.
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DIscUssION
We considered employing GFs for therapeutic 
purposes in order to improve choroidal flow, slow down 
RPE cells and photoreceptor apoptosis, and ultimately 
curb retinal worsening in dry AMD patients treated with 
LRRT. Moreover, we assumed that a greater number of 
residual cells could lead to a greater interaction between 
GFs and chorioretinal cellular membrane receptors, 
to more intense cellular activity and, ultimately, to an 
improvement of VP. Since GFs and neurotrophins usually 
have a short half-life, the promotion of retinal cell survival 
needs continuous and frequent administration of these 
factors. Their short half-life and the consequent need to 
perform frequent intravitreal injections with the ensuing 
complications have not allowed therapeutic use in humans 
so far [8-10].
To overcome these drawbacks, each eye of our 
subjects received cellular autograft according to LRRT, 
after the harvest of SVF with ADSCs and Platelet Rich 
Plasma, an innovation of Pelaez-Meduri’s intervention [4, 
12, 13, 19]. They used a transplantation of autologous fat 
in the subscleral space, obtaining relevant but transient 
results [5, 19]. The goals of LRRT, that is the grafting of 
the suprachoroidal adipose pedicle, of ADSCs in SVF and 
intrapeduncolar PRP were to:
1. Promote vascular pedicle fat engraftment with the 
underlying choroid;
2. Enhance pedicle fat original vascularization in 
order to ensure its volume and survival;
3. Initiate a regenerative start-up of all the retinal 
elements through the secretion of paracrine GFs.
Knowing the amount of cells in the retina could be 
useful for both rehabilitators and surgeons in order to plan 
a cell therapy with an acceptable predictive power in low 
vision patient with dry AMD. Moreover, we observed that 
cone-rod ERG and rod ERG present a highly significant 
correlation with RTA, while cone ERG does not, since 
the main functional expression of fovea appears to be 
compromised also with still regular macular volumes in 
Table 3: Patient compliance analysis  (PCA) shows that, at 6 months post surgery, 19 of 36 eyes  (52.78%) recorded 
better vision, 14 (38.89%) no change in functional situation, and 3 (8.33%) a worsening. 
PcA Group A Group b total
Number of eyes 14 22 36
Improved (%) 5 (35.71) 14 (63.64) 19 (52.78)
Unchanged (%) 7 (50) 7 (31.82) 14 (38.89)
Worse (%) 2 (14.29) 1 (4.55) 3 (8.33)
Among the 19 eyes of patients who noted an improvement at 6 months post surgery, 5 (26.3%) belong to group A and 14 
(73.7%) to group B.
Figure 1: the level of scotopic (rod-cone or maximal) electroretinogram (ErG) is different in A and b groups depending 
on retinal thickness. Case report of group A (left panel). The retinal thickness average (RTA) measured by optical coherence tomography 
(OCT) is very low (235 microns). At 180 days post surgery we obtained a slight improvement in close-up visus. Case report of group B 
(right panel). The RTA is good (277 microns) and the various cell layers are well represented in the OCT. At 180 days post surgery 
we obtained a good improvement of best corrected visual acuity (BCVA) and close-up visus (in logMAR and Pts respectively) without 
magnification change. Also the sensitivity recorded with microperimetry (MY) increased in the areas with good cellularity. 
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dry AMD, at least in the initial stages (Figure 2) [4, 5, 19]. 
Residual retinal trophism in dry AMD, value with RTA, 
may represent a prognostic criterion for the indication 
of cellular autograft with LRRT, since better outcomes 
are found increasingly in group B. We already saw the 
positive action on retinal electrical activity in our previous 
study, and the current study has shown that scotopic ERG, 
BCVA and sensitivity detected by MY appear to be more 
intense in thicker retinas (Table 2, Figure 2, 3, and 4) [4, 
19]. On the contrary, natural evolution shows inevitable 
visual impairment, according to clinical events [1-3].
LRRT allows the grafting of 3 autologous 
components and each of the grafted elements has its own 
specific assets in GFs useful from a regenerative point of 
view.
Fat cells of the pedicle grafted and contained in the 
suprachoroidal space produce: basic fibroblast growth 
factor (bFGF), epidermal growth factor (EGF), insulin-like 
growth factor-1 (IGF-1), interleukin (IL), transforming 
growth factor-β (TGF-β), pigment-epithelium-derived 
factor (PEDF), and adiponectin [22].
ADSCs produce: bFGF, vascular endothelial growth 
factor (VEGF), macrophage colony-stimulating factor 
(M-CSF), granulocyte-macrophage colony-stimulating 
factor (GM-CSF), placental growth factor (PlGF), 
TGF-β, hepatocyte growth factor (HGF), IGF-1, IL, and 
angiogenin [15].
Platelets produce: platelet-derived growth factor 
(PDGF), IGF-1, TGF-β, VEGF, bFGF, EGF, platelet-
derived angiogenesis factor (PDAF), and thrombospondin 
(TSP) [23-25].
Therefore, following the complex process of GF-
receptor formation, a limited number of second messengers 
are generated inside the target cell. These, in turn, control 
a series of biochemical pathways in the cell by regulating 
enzyme activity and transcription factors, through a 
cascade of phosphorylation events [19-25]. Upon reaching 
the cell nucleus, the signals determine changes in the 
Figure 2: Electroretinogram (ErG) and retinal thickness average (rtA) in dry age-related macular degeneration 
(AMD) at time 0 (T0). Correlation between RTA and electrical activity (in µVolts) appears to be highly significant in relation to scotopic 
ERG: rod-cone or maximal ERG in group A (p = 0.025) and rod ERG in groups A (p = 0.006) and B (p = 0.011). Corresponding scatter 
plot graph.
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response of genes, increasing the production of proteins, 
enzymes, and cytokine transcription which all play a role 
in cell trophic control, as demonstrated by the increase in 
scotopic ERG-recorded electrical activity [19-25]. 
The main function of GFs is the external control 
of the cell cycle from the quiescent cell phase, G0 phase, 
to the entry of the cell in the G1 phase of growth. In 
addition, they can regulate the triggering of mitosis, cell 
survival, migration, and cell differentiation. Some factors, 
such as VEGF, bFGF, angiogenin, PDAF, PlGF, PDGF, 
EGF, and TGF-β promote endothelial regeneration and 
may contribute to choriocapillaris reperfusion [16, 17, 
25, 26]. VEGF, introduced with PRP, stimulates ADSC 
proliferation which in turn promotes both autologous fat 
and adipocytes survival [21, 26, 27]. Others, such as TSP 
and the PEDF, inhibit pathological neovascular processes 
[21-26]. PEDF, similarly to bFGF, has a neurotrophic 
action on photoreceptors. Some factors, such as EGF, act 
on Müller cells inducing endogenous bFGF transcription 
and strengthen the protective action of these cells on the 
retina nerve cells; EGF also stimulates ADSCs to increase 
their secretory activity [30, 29]. 
To the best of our knowledge, bFGF, IGF-1, PEDF, 
PDGF, TGF-β, and VEGF are normally secreted by 
RPE but in the presence of maculopathy with atrophic 
evolution they are pathologically deficient due to the 
involution of RPE/choriocapillaris system. Their paracrine 
secretion by cell graft helps to promote photoreceptor and 
choriocapillaris survival [2, 32, 33]. Moreover, M-CSF, 
GM-CSF, and IL have both an anti-inflammatory and 
chemotactic action on macrophages which contribute to 
the removal of intraretinal cell debris and to the function 
normally carried out by RPE [34, 35]. 
From the results of our study, LRRT may result, 
directly and indirectly, in increased choroidal perfusion 
and greater trophism of the photoreceptors through 
GF-receptor interactions and stimulation mediated by 
Müller cells and RPE cells. Subsequently, these events 
are believed to allow more intense cellular activity as 
demonstrated by the improvement in electrical activity 
[4, 19]. It is logically supposed that the bond between 
cells and GF could be the necessary link in the chain of 
events responsible for an improvement of VP in dry AMD 
patients. Obviously, poor tissue cellularity would not allow 
the desired therapeutic effect due to scarce GF-membrane 
receptor interactions.
Ultimately, our results allow us to conclude that the 
technique offers some advantages in providing benefits to 
Figure 3: Values recorded from time 0 (t0) to time at 6 months (t180) after Limoli retinal restoration technique 
(LRRT). Panel A. Best corrected visual acuity (BCVA) recorded a slight increase (5.16%) in group A and a greater increase (30.51%) in 
group B. Panel B. After LRRT, close-up visus (in Pts) evaluated by magnification reaches or maintains values below 10 points (Pts) in both 
groups. Panel C. The average retinal sensitivity (in dB) recorded by microperimetry (MY) 6 months after cellular autograft increases in 
both groups: +6.88% in group A and +15.23% in group B. Retinal thickness average (RTA).
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Figure 4: corresponding scatter plot graphs of the values recorded from time 0 (t0) to time at 6 months (t180) 
after Limoli Retinal Restoration Technique (LRRT). Best corrected visual acuity (BCVA) (in logMAR); close-up visus (in Pts) 
evaluated by magnification reaches or maintains values below 10 Pts in both groups; retinal sensitivity (in dB).
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patients suffering from dry AMD. Vice versa, the surgical 
procedures available to date are more complex and only 
temporarily effective [6-13]. Obviously, our studies also 
have limits to overcome, such as further validation with a 
greater number of patients and histopathological findings 
that could provide scientific evidence for the results. Also 
a control group will be included in the next research study 
to exclude a placebo effect.
Therefore, we will continue our studies to provide 
useful updates to the scientific world on this disease which 
is responsible for growing disability in the modern world 
due to aging and will therefore have a growing burden on 
society.
cONcLUsIONs
Cell therapy by autologous cell graft in the 
suprachoroidal space according to LRRT seems to 
afford a functional improvement in retinal residual cells, 
proportional to their condition, with positive consequences 
on patient VP. The preliminary reading of OCT may allow 
rehabilitators and surgeons to plan this type of surgery/
therapy in patients with dry AMD. Including in severe 
cases the contribution of GFs to the residual cells of 
the retina allows the optimization of rehabilitation and 
recovery of lost capacity with appropriate magnifying 
systems.
PAtIENts AND MEtHODs
The tenets of the Declaration of Helsinki were 
observed, and written informed consent approval by 
the Ethics Committee of the Low Vision Academy was 
obtained.
For this purpose, we included 36 eyes of 25 patients 
(16 women and 9 men), with an average age of 75.96 years 
(range from 64 to 84 years of age) affected with dry AMD. 
They were identified and enrolled according to 
several characteristics. The inclusion criteria were: 
• Caucasian patients classified as well-nourished; 
• age ranging from 64 to 84 years;
• dry AMD diagnosis with SD-OCT, fundus 
autofluorescence imaging, and angiography in 
the presence of drusen and irregularities of RPE 
in at least 1 eye;  
• well-preserved extrafoveal areas;  
• measurable visual acuity not influenced by lens 
opacity;  
• normal intraocular pressure;  
• acceptance of the clinical protocol by signing 
the informed consent. 
The criteria for exclusion from the study due to 
possible cross interference with the test were as follows: 
• patients with signs of exudative AMD;
• myopia or hypermetropy with spherical 
equivalent of ≥ 6 diopters;
• cataract, chorioretinal and neovascular 
membrane-associated disorders, macular 
pucker, uveitis, etc.;
• other ocular disorders, such as glaucoma, optic 
neuritis, ocular trauma, high refractive errors, 
etc.; 
• insufficient compliance in individuals affected 
by medical problems, such as hypovitaminoses, 
multiple sclerosis, epilepsy, Parkinson’s disease, 
diabetes mellitus, hypertension, vasculitis, 
renal and hepatic diseases, gastrointestinal 
malabsorption, hypothyroidism, malignant 
neoplasias, and other systemic acute or chronic 
diseases. 
The eyes were retrospectively divided into two 
groups according to RTA: group A in which RTA was less 
than 250 µm, and group B in which RTA was equal to 
or greater than 250 µm (Figure 1). For each patient we 
evaluated the visual acuity for far and near distance at T0. 
BCVA was measured with ETDRS charts at 4 meters in 
logMAR and visual acuity for near vision, close-up, in Pts 
indicating the necessary zoom factor (X). The diagnosis of 
dry AMD was confirmed by Nidek F10 confocal scanning 
laser ophthalmoscope (Nidek Inc, Fremont, CA), Cirrus 
5000 SD-OCT (Carl Zeiss Meditec AG, Jena, Germany), 
and Maia 100809 MY (CenterVue S.p.A., Padua, Italy). 
Therefore, we recorded electrical cell activity through 
scotopic and photopic ERG (ocular electrophysiology 
electromedical system, Retimax; C.S.O. S.r.l., Scandicci, 
Italy) according to the standards set in 2009 by the 
International Society for Clinical Electrophysiology of 
Vision (ISCEV) [19].
Fat tissue was collected and purified from the 
abdominal subcutaneous layer of patients according to the 
Lawrence and Coleman [20] technique. Briefly, 10 mL 
of fat tissue was harvested manually from each patient 
with a 3 mm blunt cannula (Mentor, Santa Barbara, CA) 
connected to a Luer-LokTM syringe (BD Biosciences, 
Franklin Lakes, NJ). Pure SVF of fat tissue was separated 
from blood, fat, oil, and liquid after 3’ of centrifugation 
at 3200 rpm at 1200 G. For PRP preparation, 8 mL of 
human peripheral blood was collected in a Regen-BCT 
tube (RegenKit; RegenLab, Le Mont-sur-Lausanne, CH). 
The collected blood was centrifuged for 5’ at 1500 G. In 
the LRRT variant, the following changes were made to 
increase autologous fat graft survival, to trigger ADSC 
proliferation in order to promote increased choroidal 
perfusion, and to obtain a more complete modulation of 
the action of factors secreted only by fat [15, 17, 19-21].
1. The distance between the grafted autologous 
cells and choroid was reduced by deep 
sclerectomy to favor the paracrine secretion of 
the autologous cells into the choroidal flow. 
2. For the same reason, the area of contact 
between the stalk and choroid was expanded. 
3. The suprachoroidal pocket was built to 
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accommodate the graft and saturated with a 
mixture of ADSCs and SVF obtained according 
to the Lawrence and Coleman technique [20].
4. The adipose pedicle was infiltrated with PRP 
gel obtained by centrifugation of the blood 
material, separation of the component, and its 
platelet degranulation [16]. 
The details are as follows: 
• A deep scleral door of about 5 mm was opened 
by radial hinge in the infero-temporal quadrant 
at 8 mm from the limbus. The sclerectomy must 
be deep enough to allow viewing of the slate 
color of the choroid. 
• Orbital fat was extracted from a gap above the 
inferior oblique muscle. The extracted pedicle 
fat must be sufficient to ensure the survival of 
the vascular scaffold after its location. 
• The flap of autologous fat was laid gently on 
the bed and sutured with choroidal vicryl 6/0 at 
the proximal edge of the door.  
• The scleral flap was then secured to avoid 
compression on the fat pedicle or on its nutrient 
vessels.  
• The remaining space between the autologous fat 
graft, choroid, and scleral flaps was saturated 
with 0.5 cc of SVF, previously prepared with 
ADSCs by venflon inserted into the scleral 
pocket.  
• Then, the stroma of the peduncle was infiltrated 
with 1 cc of PRP using a 25-gauge cannula. 
Therefore, an autograft consisting of fat cells, 
ADSCs from SVF, and PRP was obtained.
The functional analysis was then repeated after 180 
days. Particularly, we considered BCVA and close-up visus 
after visual rehabilitation and the necessary magnification 
factor, retinal sensitivity, PCA, RTA, and ERG activity in 
both groups. 
statistical Analysis
Student’s t-test was used to compare mean age 
between the two study groups. Gender distribution was 
compared by chi square test. In order to take into account 
multiple eyes for the same patients, a Mixed linear 
regression model was used to evaluate the difference 
in this parameter at T0 between the two groups and 
the variation at T0 and T180, and to compare the mean 
change between the two groups. A p value of < 0.05 was 
considered statistically significant. All statistical analyses 
were performed with STATA 14.0 (Collage Station, Texas, 
USA).
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